Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
HCW BIOLOGICS INC (HCWB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.04-3.70%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for HCWB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage capital structure with reverse stock split and equity sales | A supporting condition in HCW BIOLOGICS INC's published investment case. The stated target is Complete capital structure actions to support stability by mid-2026. | Improving | Fail to maintain capital structure leading to liquidity issues | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative clinical-development company, not a proven compounder, with a high-risk profile and ongoing losses. The long-term thesis is intact for now because the recent performance remains in the top half of its industry, though management execution has been volatile.
HCWB is described as cheap versus peers, but the valuation model has low confidence and the expectations gap is negative. The evidence labels the current pricing as justified and fragility as low, but it does not establish that the business is inexpensive on a reliable earnings basis.
Near term, results may remain uneven: the company reported $6.5 million in revenue in 2026-Q1 and a $5.2 million net loss in 2026-Q2, while clinical development continues. HCW9302’s Phase 1 trial is progressing, with a full data readout expected in Q4 2026; licensing progress is mixed, and equity financings and a reverse stock split show ongoing capital and listing pressures.
The multi-year thesis depends on clinical progress and whether licensing efforts produce sustained collaboration revenue. A guidance cut or continued weakness in employment data would add near-term risk, while strong results and guidance from sector peers could support the healthcare backdrop.
Over the next 1 to 3 years, HCWB’s setup rests on converting clinical and licensing progress into a stronger financial footing, while managing losses, financing needs, and volatile execution. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Revenue growth to at least $6.5 million and net income improvement |
| Net income improved from a loss of $2.2 million to a profit of $3.47 million. |
| Broken |
| Revenue or net income falls below 2026-Q1 levels going forward |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Maintain Nasdaq listing compliance including minimum bid price | The company is fixing Nasdaq compliance problems. | Under Pressure | Company loses Nasdaq compliance again | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “On June 29, 2026, HCW Biologics Inc. (the “Company”) received written notice form the Listing Qualifications Staff (the “Staff”) of the Nasdaq Capital Market Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) found that the Company regained compliance with Listing Rule 5550(a)(2), the “Bid Price Rule,” per the terms set forth in the Panel’s decision letter dated May 29, 2026, as amended.” “On June 30, 2026, the Company effected a one-for-six reverse stock split.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-2.64 → $-1.05 · observed estimates
$0.03B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-07-25 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-07-26 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-07-27 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-07-28 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-07-29 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-07-30 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-07-31 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-01 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-02 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-03 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-04 | $-2.64 | $0 | 1 / 1 |
| 2026-08-05 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-06 | $-2.64 | $0 | 1 / 1 |
| 2026-08-07 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-08 | $-2.64 | $0 | 1 / 1 |
| 2026-08-09 | $-2.64 | $0 | 1 / 1 |
| 2026-08-10 | $-2.64 | $0 | 1 / 1 |
| 2026-08-12 | $-2.64 | $0 | 1 / 1 |
| 2026-08-13 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-14 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-15 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-16 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-17 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-18 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-19 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-20 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-21 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-22 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-23 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-24 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-25 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-26 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-27 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-28 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-29 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-30 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-08-31 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-01 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-02 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-03 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-04 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-05 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-06 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-07 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-08 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-09 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-10 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-11 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-12 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-13 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-14 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-15 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-16 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-17 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-18 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-19 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-20 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-21 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-22 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-23 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-24 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-25 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-26 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-27 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-28 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-29 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-09-30 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-10-01 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-10-02 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-10-03 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-10-04 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-10-05 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-10-06 | $-2.64 | $33,730,000 | 1 / 1 |
| 2026-10-07 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-08 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-09 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-10 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-11 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-12 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-13 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-14 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-15 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-16 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-17 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-18 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-19 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-20 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-21 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-22 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-23 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-24 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-25 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-26 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-27 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-28 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-29 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-30 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-10-31 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-11-01 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-11-02 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-11-03 | $-1.05 | $33,730,000 | 1 / 1 |
| 2026-11-04 | $-1.05 | $33,730,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.